Adding pharmacogenomics to the development of new marine-derived anticancer agentsReport as inadecuate

Adding pharmacogenomics to the development of new marine-derived anticancer agents - Download this document for free, or read online. Document in PDF available to download.

Journal of Translational Medicine

, 4:3

First Online: 09 January 2006Received: 12 September 2005Accepted: 09 January 2006DOI: 10.1186-1479-5876-4-3

Cite this article as: Jimeno, J., Aracil, M. & Tercero, J.C. J Transl Med 2006 4: 3. doi:10.1186-1479-5876-4-3


Nature has always been a highly productive tool in the development of anticancer therapies. Renewed interest in the potential of this tool has recently been sparked by the realization that the marine ecosystem can be used for the discovery and development of new compounds with clinical potential in advanced resistant tumors. These compounds can be incorporated into combination approaches in a chronic therapy scenario. Our marine anticancer program is using the sea to develop new agents with activity in resistant solid tumors and to identify new cellular targets for therapeutic intervention. This review describes the integration of different pharmacogenomic tools in the development of Yondelis™, Aplidin and Kahalalide F, three marine-derived compounds currently in Phase II or III development. Our results are reinforcing the targeted selectivity of these agents and opening the gates for customized therapies in cancer patients in the near future.

Electronic supplementary materialThe online version of this article doi:10.1186-1479-5876-4-3 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: José Jimeno - Miguel Aracil - Juan Carlos Tercero


Related documents